Professor of Psychiatry and Pediatrics
Anthony L. Rostain, M.D., M.A. is Professor of Psychiatry and Pediatrics at the Perelman School of Medicine of the University of Pennsylvania. He is Director of Education for the Department of Psychiatry where he is responsible for overseeing medical student education, residency, and fellowship training. He is triple boarded in pediatrics, adult psychiatry, and child and adolescent psychiatry. His primary clinical focus is "lifespan neurodevelopmental psychiatry," treating patients of all ages with Attention-Deficit/Hyperactivity Disorder, Autistic Spectrum Disorders (including Asperger Syndrome/High Functioning Autism), Tourette Syndrome, Learning Disabilities (Verbal and Nonverbal), and social communication disorders. He is an attending and supervising psychiatrist at The Children's Hospital of Philadelphia (CHOP) and University of Pennsylvania Heath System (UPHS). Dr. Rostain is the Director of the Adult Development Disorders Unit (Penn Behavioral Health) which includes the Adult ADHD Treatment and Research Program and the Adult Social Learning Disorders Program. He is also Director of The Children's Hospital of Philadelphia Behavioral Health Center's Developmental Neuropsychiatry Program where he participates in clinical care, research, and educational activities. Dr. Rostain is also a faculty member in the Center for Neuroscience and Society where he participates in research seminars and teaches about clinical applications and ethical aspects of cognitive neuroscience. Most recently, he has been active in addressing the growing trend toward non medical use of stimulants for cognitive enhancement. Dr. Rostain's research interests have focused on improving clinical outcomes for patients with ADHD and other neuropsychiatric disorders, and in creating effective service systems for high risk children, youth, and families. He completed a study of combined medication and cognitive-behavioral therapy (CBT) for adults with ADHD which served as the basis of a textbook on this topic. He is currently involved in studies of differential therapeutic efficacy of medication and CBT, of developmental processes in young adults with ADHD, and of predictors of treatment response for patients with co-morbid conditions such as anxiety and substance abuse.